Overview

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

Status:
Recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

In adults with COVID-19 without criteria for hospitalization or oxygen therapy but with risk factors for aggravation, early treatment may avoid hospitalization, indication for oxygen therapy or death. No treatment is currently validated for this indication.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University Hospital, Bordeaux

Collaborator:

University of Bordeaux

Treatments:

Ciclesonide
Hydroxychloroquine
Imatinib Mesylate
Interferon beta-1b
Interferon-beta
Interferons
Telmisartan